-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of September 6, the National Medical Insurance Bureau issued the "Announcement on Publicizing the Drugs and Related Information Of the 2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue Adjustment through Preliminary Formal Examination" (hereinafter referred to as the "Announcement"), a total of 344 varieties passed the preliminary examination, including 199 Western medicines and proprietary Chinese medicines outside the catalogue, and 145 Western medicines and proprietary Chinese medicines in the catalogue, and the publicity time was one week (until the 12th).
According to the Interpretation of the Announcement of the List of Drugs That Passed preliminary formal examination in the adjustment of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue in 2022, from 9:00 on July 1, 2022 to 17:00 on July 14, 2022, the national medical insurance information platform received a
total of 537 enterprise declarations, involving 490 drugs (generic names, the same below).
total of 537 enterprise declarations, involving 490 drugs (generic names, the same below).
After review, 344 drugs passed the preliminary form examination, and the proportion of passing was 70%.
Compared with 2021 (271 of the 474 drugs passed), the number of drugs declared and passed the preliminary form examination has increased
to a certain extent.
In terms of pass rate, the proportion of drugs outside the list is 60%, and the proportion of drugs in the list is 91%.
(See the end of the article for a detailed list)
Compared with 2021 (271 of the 474 drugs passed), the number of drugs declared and passed the preliminary form examination has increased
to a certain extent.
In terms of pass rate, the proportion of drugs outside the list is 60%, and the proportion of drugs in the list is 91%.
(See the end of the article for a detailed list)
The adjustment of the medical insurance drug list is divided into enterprise declaration, formal review, expert review, negotiation and bidding, etc.
, and the formal review is only one
of them.
Through the formal review, it is shown that the drug is eligible to enter the next step of expert review, and only by successfully passing all the links of the catalogue adjustment can it be finally included in the national medical insurance drug catalogue
.
, and the formal review is only one
of them.
Through the formal review, it is shown that the drug is eligible to enter the next step of expert review, and only by successfully passing all the links of the catalogue adjustment can it be finally included in the national medical insurance drug catalogue
.
Nearly 90 tumor drugs "dominate the list"
Imported PD-(L)1 collective "voice loss"?
From the perspective of indications, anti-tumor and immunomodulators were selected for the preliminary examination list with the largest number of 89, followed by 40 nervous system drugs, 36 systemic anti-infective drugs, and 27 respiratory system basic drugs
.
The battle for medical insurance has begun, and the tumor immunotherapy drug PD-(L)1 monoclonal antibody has become the most concerned "player"
anymore.
.
The battle for medical insurance has begun, and the tumor immunotherapy drug PD-(L)1 monoclonal antibody has become the most concerned "player"
anymore.
According to the medical insurance catalogue adjustment plan, innovative drugs or indications approved before June 30, 2022 are expected to participate in the 2022 national medical insurance negotiations and be included in the new version of the national medical insurance catalogue
.
In the case of PD-(L)1 monoclonal antibody, a total of 12 indications are pending medical insurance negotiations
.
.
In the case of PD-(L)1 monoclonal antibody, a total of 12 indications are pending medical insurance negotiations
.
Up to now, 14 PD-1/L1 monoclonal antibodies and 1 PD-1+CTLA-4 dual antibodies have been approved for listing, of which 10 PD-1 monoclonal antibodies (8 domestic and 2 imported), 4 PD-L1 monoclonal antibodies (2 domestic, 2 imported), and 1 PD-1+CTLA-4 double antibody (domestic).
Domestic pharmaceutical companies including Cinda Biologics, Hengrui Pharmaceutical, BeiGene, Junshi Biological, Kangfang Biological, Yuheng Biological, Fuhong Henlin, CStone Pharmaceutical, Corning Jereh/Idea Di/Simcere Pharmaceutical all have PD-(L)1 products participating in the competition
.
Domestic pharmaceutical companies including Cinda Biologics, Hengrui Pharmaceutical, BeiGene, Junshi Biological, Kangfang Biological, Yuheng Biological, Fuhong Henlin, CStone Pharmaceutical, Corning Jereh/Idea Di/Simcere Pharmaceutical all have PD-(L)1 products participating in the competition
.
Judging from the preliminary list, there are Henlius Henlius' Slullimonumab Injection, Corning Jerry's Envolli Monoclonal Antibody Injection, and Kangfang Bio's Cadonilimonumab Injection shortlisted, which also means that Yuheng Biologics and CStone Pharmaceutical's PD-(L)1 products will undoubtedly not be eligible for this year's medical insurance catalog
.
.
Surprisingly, the imported PD-(L)1 products that accompany the run all year round, the medical insurance negotiations directly collectively "lost their voices", whether it is Merck's Pambolizumab, BMS's Navuliyuzumab, or Roche's atiolizumab, AstraZeneca's dovaliblizumab, all did not appear in the
preliminary list.
preliminary list.
In fact, Merck's Pambolizumab, BMS's Navuliyuzumab and AstraZeneca's Dvaliyuzumab passed the preliminary list of 2021 health insurance negotiations, but from the results, 3 imported PD-(L)1 were once again absent from national health insurance
.
In the industry's view, the abandonment of medical insurance by imported enterprises is mainly due to the increasingly fierce competition in the domestic PD-(L)1 market, and the price continues to decline
.
.
In the industry's view, the abandonment of medical insurance by imported enterprises is mainly due to the increasingly fierce competition in the domestic PD-(L)1 market, and the price continues to decline
.
The first generation of domestic PD-1 "F4", Junshi Biological's Triplimonumab, Innovent Biologics' Sindilliumab, Hengrui Pharmaceutical's Carellizumab, BeiGene's Tirelizumab is expected to participate in the negotiation with new indications, this year's 4 PD-1s are added 2, 2, 4, 4 new indications, the new indications also make the PD-1/L1 market will face a more complex competitive landscape
.
.
Some analysts pointed out that due to the increase in medical insurance funds brought by new indications, it is inevitable to face further price reductions, and the negotiations on new indications this year are still very fierce
.
.
The enthusiasm of foreign companies is high
Novartis has the largest number of products
This year, 9 companies have declared more than 5 drugs, of which Novartis Pharmaceutical has participated in this year's medical insurance negotiations with 14 drugs, becoming the enterprise
with the most drugs declared in this year's medical insurance negotiations.
with the most drugs declared in this year's medical insurance negotiations.
Among Novartis' 14 drugs, except for offaldomumab injection, the rest of the drugs have previously been included in the medical insurance directory through medical insurance negotiations, and the products that have attracted much attention such as edopipala ethanolamine tablets, everolimus tablets and omalizumab for injection in the preliminary list have attracted many attention
in the medical insurance negotiations in previous years.
in the medical insurance negotiations in previous years.
In the case of edrappa ethanolamine tablets, the product was approved to enter China in December 2017 under the trade name Refrain, and its global sales reached $1.
738 billion in 2020, an increase of 23.
0% year-on-year, ranking sixth
in novartis product sales list.
Public data shows that in 2019, Atropopa's domestic sales were more than 69 million yuan
.
In 2019, edopopapalaethanolamine successfully entered the national medical insurance class B range and successfully renewed its contract
in 2020.
738 billion in 2020, an increase of 23.
0% year-on-year, ranking sixth
in novartis product sales list.
Public data shows that in 2019, Atropopa's domestic sales were more than 69 million yuan
.
In 2019, edopopapalaethanolamine successfully entered the national medical insurance class B range and successfully renewed its contract
in 2020.
In addition, the Class 1 innovative drug Sinimod tablets, which were approved for listing through the priority review and approval procedure in 2020 and successfully entered the medical insurance directory in the medical insurance negotiations of that year, also appeared on this year's medical insurance negotiation preliminary review list
.
Sinimod is used to treat adults with recurrent multiple sclerosis, a chronic disease that requires long-term medication and patients with a strong
demand for oral medications.
Novartis launched the world's first S1PR regulator for MS, Gilenya, in September 2010, the first oral therapy
to reduce the frequency of recurrence in MS patients.
.
Sinimod is used to treat adults with recurrent multiple sclerosis, a chronic disease that requires long-term medication and patients with a strong
demand for oral medications.
Novartis launched the world's first S1PR regulator for MS, Gilenya, in September 2010, the first oral therapy
to reduce the frequency of recurrence in MS patients.
In second place is Pfizer, which has 11 drugs negotiated for health insurance this year, of which piperacill capsules and digaric acetic acid for injection also appeared on the preliminary list
last year.
last year.
Ranked third is Jiangsu Hengrui, as a traditional pharmaceutical company transforming from generic drugs to innovative drugs, Hengrui participated in the medical insurance negotiations with 10 products, full of sincerity, including proline hengliflozin tablets, dalcilly tablets of isethionate, reviruter tablets, pyrrolinib maleate tablets and 5 domestic original research drugs
of ramazolam tosylate for injection.
Among them, proline hengliflozin tablets are a class 1 new drug approved for marketing at the end of 2021, and it is also the first domestic innovative SGLT-2 inhibitor
.
of ramazolam tosylate for injection.
Among them, proline hengliflozin tablets are a class 1 new drug approved for marketing at the end of 2021, and it is also the first domestic innovative SGLT-2 inhibitor
.
The number of drugs declared by Sanofi (Beijing), AstraZeneca (Wuxi) and Chia Tai Tianqing was 7; Bayer declared 6 drugs; Jiangsu Haosen and BeiGene (Beijing) declared 5 drugs
.
.
"Sky-high price" CAR-T products have attracted attention again
Chinese medicine enterprises actively become a "big year"
Some special drug areas also deserve market attention
.
.
WuXi Junuo brought the second domestic CAR-T product, Ricky Ollense Injection (Cigna), which was approved for marketing in September 2021 and entered the medical insurance negotiation directory
for the first time this year.
for the first time this year.
In fact, this is the second time that products in the CAR-T field have launched an impact
on the medical insurance directory.
Last year, Fosun Kate's application for medical insurance negotiations with the country's first approved CAR-T product Agilense injection also attracted widespread attention, and the price of 1.
2 million / piece attracted market attention, but the negotiation of the product ended in failure; In this year's preliminary list, Aguilonsay injection has been difficult to find
.
on the medical insurance directory.
Last year, Fosun Kate's application for medical insurance negotiations with the country's first approved CAR-T product Agilense injection also attracted widespread attention, and the price of 1.
2 million / piece attracted market attention, but the negotiation of the product ended in failure; In this year's preliminary list, Aguilonsay injection has been difficult to find
.
The purchase price of Ricky Ollense injection 1.
29 million / needle is 90,000 yuan more expensive than Fosun Kate's 1.
2 million / needle Agironse injection, with the lessons of Fosun Kate last year, WuXi Junuo product pricing this time is still actively declaring medical insurance negotiations, is it to attract traffic, or really have the confidence to suppress the product price and face the medical insurance negotiation "soul bargaining"? "How much has fallen" has also become the focus
of public attention.
29 million / needle is 90,000 yuan more expensive than Fosun Kate's 1.
2 million / needle Agironse injection, with the lessons of Fosun Kate last year, WuXi Junuo product pricing this time is still actively declaring medical insurance negotiations, is it to attract traffic, or really have the confidence to suppress the product price and face the medical insurance negotiation "soul bargaining"? "How much has fallen" has also become the focus
of public attention.
In the field of proprietary Chinese medicine, back in December 2021, the Office of the State Medical Security Administration and the Office of the State Administration of Traditional Chinese Medicine jointly issued the "Guiding Opinions of the State Medical Security Administration and the State Administration of Traditional Chinese Medicine on Medical Insurance supporting the inheritance and innovative development of traditional Chinese medicine" to put forward suggestions for
supporting the innovation and development of traditional Chinese medicine.
The opinions propose that appropriate traditional Chinese medicine and traditional Chinese medicine medical service projects should be included in the scope of
medical insurance payment.
supporting the innovation and development of traditional Chinese medicine.
The opinions propose that appropriate traditional Chinese medicine and traditional Chinese medicine medical service projects should be included in the scope of
medical insurance payment.
In the preliminary examination catalogue, respiratory disease drugs such as Golden Lotus Effervescent Tablets of LiLi Pharmaceutical, digestive disease drugs such as Shaanxi Jianmin's Qirui Gastric Shu Capsules, Ruyi Zhenbao Tablets of Qizheng Tibetan Medicine, and Lipid-Lowering Tongluo Softgels of Shenwei Pharmaceutical are still the mainstream drugs in the medical insurance catalogue in the field of proprietary Chinese medicine
.
.
It is worth noting that a number of enterprises such as Tianjin Tasly and Jilin Huakang have brought pediatric drugs
such as peony antispasmodic granules and dredging granules.
While promoting the development of traditional Chinese medicine products, it also enriches the choice
of pediatric drugs.
It breaks the limitation that pediatric drugs in the previous medical insurance catalogue are only Western medicines
.
such as peony antispasmodic granules and dredging granules.
While promoting the development of traditional Chinese medicine products, it also enriches the choice
of pediatric drugs.
It breaks the limitation that pediatric drugs in the previous medical insurance catalogue are only Western medicines
.
In addition, the National Medical Insurance Bureau said that in the context of the normalization of epidemic prevention and control, the National Medical Insurance Bureau attaches great importance to the treatment of new crown pneumonia drugs, and will include drugs in the "diagnosis and treatment plan for new coronavirus pneumonia" as one
of the declaration conditions.
In the new version of the new crown diagnosis and treatment plan, a number of new crown treatment drugs newly listed in China are included, among which China's first new crown oral drug Azifudine tablets have also passed the preliminary review list
.
of the declaration conditions.
In the new version of the new crown diagnosis and treatment plan, a number of new crown treatment drugs newly listed in China are included, among which China's first new crown oral drug Azifudine tablets have also passed the preliminary review list
.
Rare diseases are attracting renewed attention
Sanofi accelerated across the board
After the phrase "every small group should not be abandoned" in the national medical insurance negotiations at the end of 2021 triggered public opinion, the demand for drugs for the treatment of rare diseases and rare diseases was known to the
public.
public.
In this year's preliminary catalogue, on the basis of continuing to support innovative drugs, the focus
on drugs for the treatment of rare diseases is also highlighted.
According to statistics, there are nearly 20 drugs
in the field of rare diseases and rare diseases in the preliminary examination list.
on drugs for the treatment of rare diseases is also highlighted.
According to statistics, there are nearly 20 drugs
in the field of rare diseases and rare diseases in the preliminary examination list.
Last year, The sodium injection of Northinasone, which was once as high as 700,000 / needle, fell to the "civilian price", which caused widespread concern in
the pharmaceutical market.
This year, risperolam oral solution, which is also used as a treatment for spinal muscular atrophy (SMA), was also included in the preliminary examination catalogue
.
the pharmaceutical market.
This year, risperolam oral solution, which is also used as a treatment for spinal muscular atrophy (SMA), was also included in the preliminary examination catalogue
.
It is worth noting that multinational pharmaceutical companies such as Sanofi and Takeda have more than one drug shortlisted in this field
.
Military? The two drugs developed are anti-heritability? Larnaliyumab injection for tubular edema, verandidase α for injection of drugs for the treatment of type 1 Gaucher disease
.
.
Military? The two drugs developed are anti-heritability? Larnaliyumab injection for tubular edema, verandidase α for injection of drugs for the treatment of type 1 Gaucher disease
.
Sanofi has the largest number of products, with 4 products shortlisted for preliminary examination, including cytarabidase α for injection for the treatment of Pompe disease, agasase β for injection for Fabre disease, laronise concentrate solution for injection for mucopolysaccharide storage disease, and imidase for injection for Gaucher disease
.
.
In addition, The injection of brosoyomab for the treatment of hypophosphate rickets by Concord Fermentation Kirin (China) Pharmaceutical Co.
, Ltd.
, the injection of of offlatumab for novartis for the treatment of multiple sclerosis, and the dimethyl fumarate enteric-coated capsules for bohair for the treatment of multiple sclerosis are also on the
preliminary list.
, Ltd.
, the injection of of offlatumab for novartis for the treatment of multiple sclerosis, and the dimethyl fumarate enteric-coated capsules for bohair for the treatment of multiple sclerosis are also on the
preliminary list.
Local companies have also begun to "march forward" in the field of rare diseases! Aidu sulfaseß injection for the treatment of mucopolysaccharide storage disease type II in Sinoai Pharmaceutical, Riluzole oral suspension for the treatment of amyotrophic lateral sclerosis developed by Guangzhou Zhaoke Lianfa Pharmaceutical, nitezine capsules of Type I of Hanguang Pharmaceutical for the treatment of tyrosinemia, sodium phenylbutyrate granules for the treatment of urea circulation disorders in Zhaoke Pharmaceutical, Huperzine A injection for the treatment of myasthenia gravis by Wanbond Pharmaceutical, and Inelizumabumab injection for the treatment of optic nerve myelitis by Hengbang Pharmaceutical.
The list is as follows:
On the evening of September 6, the National Medical Insurance Bureau issued the "Announcement on Publicizing the Drugs and Related Information Of the 2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue Adjustment through Preliminary Formal Examination" (hereinafter referred to as the "Announcement"), a total of 344 varieties passed the preliminary examination, including 199 Western medicines and proprietary Chinese medicines outside the catalogue, and 145 Western medicines and proprietary Chinese medicines in the catalogue, and the publicity time was one week (until the 12th).
According to the Interpretation of the Announcement of the List of Drugs That Passed preliminary formal examination in the adjustment of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue in 2022, from 9:00 on July 1, 2022 to 17:00 on July 14, 2022, the national medical insurance information platform received a
total of 537 enterprise declarations, involving 490 drugs (generic names, the same below).
Pharmaceuticalstotal of 537 enterprise declarations, involving 490 drugs (generic names, the same below).
After review, 344 drugs passed the preliminary form examination, and the proportion of passing was 70%.
Compared with 2021 (271 of the 474 drugs passed), the number of drugs declared and passed the preliminary form examination has increased
to a certain extent.
In terms of pass rate, the proportion of drugs outside the list is 60%, and the proportion of drugs in the list is 91%.
(See the end of the article for a detailed list)
Compared with 2021 (271 of the 474 drugs passed), the number of drugs declared and passed the preliminary form examination has increased
to a certain extent.
In terms of pass rate, the proportion of drugs outside the list is 60%, and the proportion of drugs in the list is 91%.
(See the end of the article for a detailed list)
The adjustment of the medical insurance drug list is divided into enterprise declaration, formal review, expert review, negotiation and bidding, etc.
, and the formal review is only one
of them.
Through the formal review, it is shown that the drug is eligible to enter the next step of expert review, and only by successfully passing all the links of the catalogue adjustment can it be finally included in the national medical insurance drug catalogue
.
, and the formal review is only one
of them.
Through the formal review, it is shown that the drug is eligible to enter the next step of expert review, and only by successfully passing all the links of the catalogue adjustment can it be finally included in the national medical insurance drug catalogue
.
Nearly 90 tumor drugs "dominate the list"
Nearly 90 tumor drugs "dominate the list" Imported PD-(L)1 collective "voice loss"?
Imported PD-(L)1 collective "voice loss"? From the perspective of indications, anti-tumor and immunomodulators were selected for the preliminary examination list with the largest number of 89, followed by 40 nervous system drugs, 36 systemic anti-infective drugs, and 27 respiratory system basic drugs
.
The battle for medical insurance has begun, and the tumor immunotherapy drug PD-(L)1 monoclonal antibody has become the most concerned "player"
anymore.
.
The battle for medical insurance has begun, and the tumor immunotherapy drug PD-(L)1 monoclonal antibody has become the most concerned "player"
anymore.
According to the medical insurance catalogue adjustment plan, innovative drugs or indications approved before June 30, 2022 are expected to participate in the 2022 national medical insurance negotiations and be included in the new version of the national medical insurance catalogue
.
In the case of PD-(L)1 monoclonal antibody, a total of 12 indications are pending medical insurance negotiations
.
.
In the case of PD-(L)1 monoclonal antibody, a total of 12 indications are pending medical insurance negotiations
.
Up to now, 14 PD-1/L1 monoclonal antibodies and 1 PD-1+CTLA-4 dual antibodies have been approved for listing, of which 10 PD-1 monoclonal antibodies (8 domestic and 2 imported), 4 PD-L1 monoclonal antibodies (2 domestic, 2 imported), and 1 PD-1+CTLA-4 double antibody (domestic).
Domestic pharmaceutical companies including Cinda Biologics, Hengrui Pharmaceutical, BeiGene, Junshi Biological, Kangfang Biological, Yuheng Biological, Fuhong Henlin, CStone Pharmaceutical, Corning Jereh/Idea Di/Simcere Pharmaceutical all have PD-(L)1 products participating in the competition
.
MedicineDomestic pharmaceutical companies including Cinda Biologics, Hengrui Pharmaceutical, BeiGene, Junshi Biological, Kangfang Biological, Yuheng Biological, Fuhong Henlin, CStone Pharmaceutical, Corning Jereh/Idea Di/Simcere Pharmaceutical all have PD-(L)1 products participating in the competition
.
Judging from the preliminary list, there are Henlius Henlius' Slullimonumab Injection, Corning Jerry's Envolli Monoclonal Antibody Injection, and Kangfang Bio's Cadonilimonumab Injection shortlisted, which also means that Yuheng Biologics and CStone Pharmaceutical's PD-(L)1 products will undoubtedly not be eligible for this year's medical insurance catalog
.
.
Surprisingly, the imported PD-(L)1 products that accompany the run all year round, the medical insurance negotiations directly collectively "lost their voices", whether it is Merck's Pambolizumab, BMS's Navuliyuzumab, or Roche's atiolizumab, AstraZeneca's dovaliblizumab, all did not appear in the
preliminary list.
preliminary list.
In fact, Merck's Pambolizumab, BMS's Navuliyuzumab and AstraZeneca's Dvaliyuzumab passed the preliminary list of 2021 health insurance negotiations, but from the results, 3 imported PD-(L)1 were once again absent from national health insurance
.
In the industry's view, the abandonment of medical insurance by imported enterprises is mainly due to the increasingly fierce competition in the domestic PD-(L)1 market, and the price continues to decline
.
Enterprise enterprise.
In the industry's view, the abandonment of medical insurance by imported enterprises is mainly due to the increasingly fierce competition in the domestic PD-(L)1 market, and the price continues to decline
.
The first generation of domestic PD-1 "F4", Junshi Biological's Triplimonumab, Innovent Biologics' Sindilliumab, Hengrui Pharmaceutical's Carellizumab, BeiGene's Tirelizumab is expected to participate in the negotiation with new indications, this year's 4 PD-1s are added 2, 2, 4, 4 new indications, the new indications also make the PD-1/L1 market will face a more complex competitive landscape
.
.
Some analysts pointed out that due to the increase in medical insurance funds brought by new indications, it is inevitable to face further price reductions, and the negotiations on new indications this year are still very fierce
.
.
The enthusiasm of foreign companies is high
The enthusiasm of foreign companies is high Novartis has the largest number of products
Novartis has the largest number of products This year, 9 companies have declared more than 5 drugs, of which Novartis Pharmaceutical has participated in this year's medical insurance negotiations with 14 drugs, becoming the enterprise
with the most drugs declared in this year's medical insurance negotiations.
with the most drugs declared in this year's medical insurance negotiations.
Among Novartis' 14 drugs, except for offaldomumab injection, the rest of the drugs have previously been included in the medical insurance directory through medical insurance negotiations, and the products that have attracted much attention such as edopipala ethanolamine tablets, everolimus tablets and omalizumab for injection in the preliminary list have attracted many attention
in the medical insurance negotiations in previous years.
in the medical insurance negotiations in previous years.
In the case of edrappa ethanolamine tablets, the product was approved to enter China in December 2017 under the trade name Refrain, and its global sales reached $1.
738 billion in 2020, an increase of 23.
0% year-on-year, ranking sixth
in novartis product sales list.
Public data shows that in 2019, Atropopa's domestic sales were more than 69 million yuan
.
In 2019, edopopapalaethanolamine successfully entered the national medical insurance class B range and successfully renewed its contract
in 2020.
738 billion in 2020, an increase of 23.
0% year-on-year, ranking sixth
in novartis product sales list.
Public data shows that in 2019, Atropopa's domestic sales were more than 69 million yuan
.
In 2019, edopopapalaethanolamine successfully entered the national medical insurance class B range and successfully renewed its contract
in 2020.
In addition, the Class 1 innovative drug Sinimod tablets, which were approved for listing through the priority review and approval procedure in 2020 and successfully entered the medical insurance directory in the medical insurance negotiations of that year, also appeared on this year's medical insurance negotiation preliminary review list
.
Sinimod is used to treat adults with recurrent multiple sclerosis, a chronic disease that requires long-term medication and patients with a strong
demand for oral medications.
Novartis launched the world's first S1PR regulator for MS, Gilenya, in September 2010, the first oral therapy
to reduce the frequency of recurrence in MS patients.
.
Sinimod is used to treat adults with recurrent multiple sclerosis, a chronic disease that requires long-term medication and patients with a strong
demand for oral medications.
Novartis launched the world's first S1PR regulator for MS, Gilenya, in September 2010, the first oral therapy
to reduce the frequency of recurrence in MS patients.
In second place is Pfizer, which has 11 drugs negotiated for health insurance this year, of which piperacill capsules and digaric acetic acid for injection also appeared on the preliminary list
last year.
last year.
Ranked third is Jiangsu Hengrui, as a traditional pharmaceutical company transforming from generic drugs to innovative drugs, Hengrui participated in the medical insurance negotiations with 10 products, full of sincerity, including proline hengliflozin tablets, dalcilly tablets of isethionate, reviruter tablets, pyrrolinib maleate tablets and 5 domestic original research drugs
of ramazolam tosylate for injection.
Among them, proline hengliflozin tablets are a class 1 new drug approved for marketing at the end of 2021, and it is also the first domestic innovative SGLT-2 inhibitor
.
of ramazolam tosylate for injection.
Among them, proline hengliflozin tablets are a class 1 new drug approved for marketing at the end of 2021, and it is also the first domestic innovative SGLT-2 inhibitor
.
The number of drugs declared by Sanofi (Beijing), AstraZeneca (Wuxi) and Chia Tai Tianqing was 7; Bayer declared 6 drugs; Jiangsu Haosen and BeiGene (Beijing) declared 5 drugs
.
.
"Sky-high price" CAR-T products have attracted attention again
"Sky-high price" CAR-T products have attracted attention again Chinese medicine enterprises actively become a "big year"
Chinese medicine enterprises actively become a "big year" Some special drug areas also deserve market attention
.
.
WuXi Junuo brought the second domestic CAR-T product, Ricky Ollense Injection (Cigna), which was approved for marketing in September 2021 and entered the medical insurance negotiation directory
for the first time this year.
for the first time this year.
In fact, this is the second time that products in the CAR-T field have launched an impact
on the medical insurance directory.
Last year, Fosun Kate's application for medical insurance negotiations with the country's first approved CAR-T product Agilense injection also attracted widespread attention, and the price of 1.
2 million / piece attracted market attention, but the negotiation of the product ended in failure; In this year's preliminary list, Aguilonsay injection has been difficult to find
.
on the medical insurance directory.
Last year, Fosun Kate's application for medical insurance negotiations with the country's first approved CAR-T product Agilense injection also attracted widespread attention, and the price of 1.
2 million / piece attracted market attention, but the negotiation of the product ended in failure; In this year's preliminary list, Aguilonsay injection has been difficult to find
.
The purchase price of Ricky Ollense injection 1.
29 million / needle is 90,000 yuan more expensive than Fosun Kate's 1.
2 million / needle Agironse injection, with the lessons of Fosun Kate last year, WuXi Junuo product pricing this time is still actively declaring medical insurance negotiations, is it to attract traffic, or really have the confidence to suppress the product price and face the medical insurance negotiation "soul bargaining"? "How much has fallen" has also become the focus
of public attention.
Procurement Procurement29 million / needle is 90,000 yuan more expensive than Fosun Kate's 1.
2 million / needle Agironse injection, with the lessons of Fosun Kate last year, WuXi Junuo product pricing this time is still actively declaring medical insurance negotiations, is it to attract traffic, or really have the confidence to suppress the product price and face the medical insurance negotiation "soul bargaining"? "How much has fallen" has also become the focus
of public attention.
In the field of proprietary Chinese medicine, back in December 2021, the Office of the State Medical Security Administration and the Office of the State Administration of Traditional Chinese Medicine jointly issued the "Guiding Opinions of the State Medical Security Administration and the State Administration of Traditional Chinese Medicine on Medical Insurance supporting the inheritance and innovative development of traditional Chinese medicine" to put forward suggestions for
supporting the innovation and development of traditional Chinese medicine.
The opinions propose that appropriate traditional Chinese medicine and traditional Chinese medicine medical service projects should be included in the scope of
medical insurance payment.
Traditional Chinese Medicine Traditional Chinese Medicinesupporting the innovation and development of traditional Chinese medicine.
The opinions propose that appropriate traditional Chinese medicine and traditional Chinese medicine medical service projects should be included in the scope of
medical insurance payment.
In the preliminary examination catalogue, respiratory disease drugs such as Golden Lotus Effervescent Tablets of LiLi Pharmaceutical, digestive disease drugs such as Shaanxi Jianmin's Qirui Gastric Shu Capsules, Ruyi Zhenbao Tablets of Qizheng Tibetan Medicine, and Lipid-Lowering Tongluo Softgels of Shenwei Pharmaceutical are still the mainstream drugs in the medical insurance catalogue in the field of proprietary Chinese medicine
.
.
It is worth noting that a number of enterprises such as Tianjin Tasly and Jilin Huakang have brought pediatric drugs
such as peony antispasmodic granules and dredging granules.
While promoting the development of traditional Chinese medicine products, it also enriches the choice
of pediatric drugs.
It breaks the limitation that pediatric drugs in the previous medical insurance catalogue are only Western medicines
.
such as peony antispasmodic granules and dredging granules.
While promoting the development of traditional Chinese medicine products, it also enriches the choice
of pediatric drugs.
It breaks the limitation that pediatric drugs in the previous medical insurance catalogue are only Western medicines
.
In addition, the National Medical Insurance Bureau said that in the context of the normalization of epidemic prevention and control, the National Medical Insurance Bureau attaches great importance to the treatment of new crown pneumonia drugs, and will include drugs in the "diagnosis and treatment plan for new coronavirus pneumonia" as one
of the declaration conditions.
In the new version of the new crown diagnosis and treatment plan, a number of new crown treatment drugs newly listed in China are included, among which China's first new crown oral drug Azifudine tablets have also passed the preliminary review list
.
of the declaration conditions.
In the new version of the new crown diagnosis and treatment plan, a number of new crown treatment drugs newly listed in China are included, among which China's first new crown oral drug Azifudine tablets have also passed the preliminary review list
.
Rare diseases are attracting renewed attention
Rare diseases are attracting renewed attention Sanofi accelerated across the board
Sanofi accelerated across the board After the phrase "every small group should not be abandoned" in the national medical insurance negotiations at the end of 2021 triggered public opinion, the demand for drugs for the treatment of rare diseases and rare diseases was known to the
public.
public.
In this year's preliminary catalogue, on the basis of continuing to support innovative drugs, the focus
on drugs for the treatment of rare diseases is also highlighted.
According to statistics, there are nearly 20 drugs
in the field of rare diseases and rare diseases in the preliminary examination list.
on drugs for the treatment of rare diseases is also highlighted.
According to statistics, there are nearly 20 drugs
in the field of rare diseases and rare diseases in the preliminary examination list.
Last year, The sodium injection of Northinasone, which was once as high as 700,000 / needle, fell to the "civilian price", which caused widespread concern in
the pharmaceutical market.
This year, risperolam oral solution, which is also used as a treatment for spinal muscular atrophy (SMA), was also included in the preliminary examination catalogue
.
the pharmaceutical market.
This year, risperolam oral solution, which is also used as a treatment for spinal muscular atrophy (SMA), was also included in the preliminary examination catalogue
.
It is worth noting that multinational pharmaceutical companies such as Sanofi and Takeda have more than one drug shortlisted in this field
.
Military? The two drugs developed are anti-heritability? Larnaliyumab injection for tubular edema, verandidase α for injection of drugs for the treatment of type 1 Gaucher disease
.
.
Military? The two drugs developed are anti-heritability? Larnaliyumab injection for tubular edema, verandidase α for injection of drugs for the treatment of type 1 Gaucher disease
.
Sanofi has the largest number of products, with 4 products shortlisted for preliminary examination, including cytarabidase α for injection for the treatment of Pompe disease, agasase β for injection for Fabre disease, laronise concentrate solution for injection for mucopolysaccharide storage disease, and imidase for injection for Gaucher disease
.
.
In addition, The injection of brosoyomab for the treatment of hypophosphate rickets by Concord Fermentation Kirin (China) Pharmaceutical Co.
, Ltd.
, the injection of of offlatumab for novartis for the treatment of multiple sclerosis, and the dimethyl fumarate enteric-coated capsules for bohair for the treatment of multiple sclerosis are also on the
preliminary list.
, Ltd.
, the injection of of offlatumab for novartis for the treatment of multiple sclerosis, and the dimethyl fumarate enteric-coated capsules for bohair for the treatment of multiple sclerosis are also on the
preliminary list.
Local companies have also begun to "march forward" in the field of rare diseases! Aidu sulfaseß injection for the treatment of mucopolysaccharide storage disease type II in Sinoai Pharmaceutical, Riluzole oral suspension for the treatment of amyotrophic lateral sclerosis developed by Guangzhou Zhaoke Lianfa Pharmaceutical, nitezine capsules of Type I of Hanguang Pharmaceutical for the treatment of tyrosinemia, sodium phenylbutyrate granules for the treatment of urea circulation disorders in Zhaoke Pharmaceutical, Huperzine A injection for the treatment of myasthenia gravis by Wanbond Pharmaceutical, and Inelizumabumab injection for the treatment of optic nerve myelitis by Hengbang Pharmaceutical.
The list is as follows:
The list is as follows:
